Onkologie. 2014:8(3):136-138

Toxicity of docetaxel treatment in patients with breast cancer

Kateřina Krošláková, Milan Kohoutek, Markéta Pospíšková

KOC, KNTB Zlín a.s.

Docetaxel is a cytostatic drug used in adjuvant, neoadjuvant as well as palliative treatment of breast cancer. It is administered as monotherapy

or as part of combination regimens. Taxanes along with anthracyclines are among the most efficacious chemotherapeutic

drugs used in the treatment of breast cancer. Inclusion of docetaxel in the therapeutic regimen for breast cancer has resulted in improved

overall survival and extended disease-free interval in patients treated with adjuvant therapy and in a greater proportion of therapeutic

responses as well as extended time-to-progression and overall survival with palliative therapy (1, 2, 3, 4, 5). It must be kept in mind that,

when used for treatment, docetaxel is a chemotherapeutic drug with non-negligible adverse effects. The aim of our retrospective study

was to evaluate acute toxicity of therapeutic regimens with docetaxel and to consider the options for the treatment of acute toxicity.

Keywords: docetaxel, breast cancer, acute toxicity, filgrastim, pegfilgrastim

Published: June 1, 2014  Show citation